Veracyte Inc (FRA:12V)
€ 32 0.6 (1.91%) Market Cap: 2.54 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 2.37 GF Score: 83/100

Veracyte Inc to Acquire HalioDx M&A Call Transcript

Jun 01, 2021 / 12:00PM GMT
Release Date Price: €31.8 (-0.62%)
Operator

Good morning, ladies and gentlemen, and welcome to Veracyte's conference call regarding its pending acquisition of HalioDx announced earlier today. As a reminder, today's conference call is being recorded.

I'd now like to turn the conference over to Tracy Morris, Veracyte's Vice President of Corporate Communications and Investor Relations. You may begin.

Tracy Morris
Veracyte, Inc. - VP of Corporate Communications & IR

Thank you, Josh. Good morning, everyone, and thanks for joining us today to review and discuss our pending acquisition of HalioDx, which we announced earlier today. With me today are Bonnie Anderson, Veracyte's Executive Chairwoman; Marc Stapley, Veracyte's Chief Executive Officer; and Vincent Fert, HalioDx' Chairman and CEO. I would also like to point out that today is Marc's first day as CEO of Veracyte. Welcome, Marc.

Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot